Research programme: antibacterials - The Medicines Company

Drug Profile

Research programme: antibacterials - The Medicines Company

Latest Information Update: 29 May 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targanta Therapeutics Corporation
  • Developer The Medicines Company
  • Class Peptides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; DNA-directed RNA polymerase inhibitors; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pseudomonal infections; Staphylococcal infections; Streptococcal infections

Most Recent Events

  • 09 Oct 2008 Preclinical development is ongoing in Canada
  • 02 Feb 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the Bacterial Infections pharmacodynamics and antimicrobial activity sections ,
  • 19 Dec 2005 Preclinical trials in Pseudomonal infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top